Copyright Reports & Markets. All rights reserved.

Global Anticancer Biologics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Anticancer Biologics by Type
    • 1.3.1 Overview: Global Anticancer Biologics Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Anticancer Biologics Consumption Value Market Share by Type in 2025
    • 1.3.3 Antibody Therapies
    • 1.3.4 Antibody-Drug Conjugates (ADCs)
    • 1.3.5 Cell Therapies
    • 1.3.6 Cancer Vaccines and Oncolytic Viruses
    • 1.3.7 Others
  • 1.4 Classification of Anticancer Biologics by Target
    • 1.4.1 Overview: Global Anticancer Biologics Market Size by Target: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Anticancer Biologics Consumption Value Market Share by Target in 2025
    • 1.4.3 Immune Checkpoint Targets
    • 1.4.4 Solid Tumor-Associated Targets
    • 1.4.5 Hematologic Tumor Targets
    • 1.4.6 Angiogenesis-Related Targets
    • 1.4.7 Others
  • 1.5 Classification of Anticancer Biologics by Route of Administration
    • 1.5.1 Overview: Global Anticancer Biologics Market Size by Route of Administration: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Anticancer Biologics Consumption Value Market Share by Route of Administration in 2025
    • 1.5.3 Intravenous Administration
    • 1.5.4 Subcutaneous Administration
    • 1.5.5 Cell Infusion
    • 1.5.6 Intratumoral Administration
    • 1.5.7 Others
  • 1.6 Global Anticancer Biologics Market by Application
    • 1.6.1 Overview: Global Anticancer Biologics Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Lung Cancer
    • 1.6.3 Breast Cancer
    • 1.6.4 Hematologic Cancers
    • 1.6.5 Gastrointestinal Cancers
    • 1.6.6 Others
  • 1.7 Global Anticancer Biologics Market Size & Forecast
  • 1.8 Global Anticancer Biologics Market Size and Forecast by Region
    • 1.8.1 Global Anticancer Biologics Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Anticancer Biologics Market Size by Region, (2021-2032)
    • 1.8.3 North America Anticancer Biologics Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Anticancer Biologics Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Anticancer Biologics Market Size and Prospect (2021-2032)
    • 1.8.6 South America Anticancer Biologics Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Anticancer Biologics Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 AbbVie Inc.
    • 2.1.1 AbbVie Inc. Details
    • 2.1.2 AbbVie Inc. Major Business
    • 2.1.3 AbbVie Inc. Anticancer Biologics Product and Solutions
    • 2.1.4 AbbVie Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 AbbVie Inc. Recent Developments and Future Plans
  • 2.2 Johnson & Johnson
    • 2.2.1 Johnson & Johnson Details
    • 2.2.2 Johnson & Johnson Major Business
    • 2.2.3 Johnson & Johnson Anticancer Biologics Product and Solutions
    • 2.2.4 Johnson & Johnson Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.3 Novartis AG
    • 2.3.1 Novartis AG Details
    • 2.3.2 Novartis AG Major Business
    • 2.3.3 Novartis AG Anticancer Biologics Product and Solutions
    • 2.3.4 Novartis AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Novartis AG Recent Developments and Future Plans
  • 2.4 Gilead Sciences, Inc.
    • 2.4.1 Gilead Sciences, Inc. Details
    • 2.4.2 Gilead Sciences, Inc. Major Business
    • 2.4.3 Gilead Sciences, Inc. Anticancer Biologics Product and Solutions
    • 2.4.4 Gilead Sciences, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Gilead Sciences, Inc. Recent Developments and Future Plans
  • 2.5 Roche
    • 2.5.1 Roche Details
    • 2.5.2 Roche Major Business
    • 2.5.3 Roche Anticancer Biologics Product and Solutions
    • 2.5.4 Roche Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Roche Recent Developments and Future Plans
  • 2.6 Bristol-Myers Squibb Company
    • 2.6.1 Bristol-Myers Squibb Company Details
    • 2.6.2 Bristol-Myers Squibb Company Major Business
    • 2.6.3 Bristol-Myers Squibb Company Anticancer Biologics Product and Solutions
    • 2.6.4 Bristol-Myers Squibb Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
  • 2.7 Amgen Inc.
    • 2.7.1 Amgen Inc. Details
    • 2.7.2 Amgen Inc. Major Business
    • 2.7.3 Amgen Inc. Anticancer Biologics Product and Solutions
    • 2.7.4 Amgen Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Amgen Inc. Recent Developments and Future Plans
  • 2.8 AstraZeneca plc
    • 2.8.1 AstraZeneca plc Details
    • 2.8.2 AstraZeneca plc Major Business
    • 2.8.3 AstraZeneca plc Anticancer Biologics Product and Solutions
    • 2.8.4 AstraZeneca plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 AstraZeneca plc Recent Developments and Future Plans
  • 2.9 Merck & Co., Inc.
    • 2.9.1 Merck & Co., Inc. Details
    • 2.9.2 Merck & Co., Inc. Major Business
    • 2.9.3 Merck & Co., Inc. Anticancer Biologics Product and Solutions
    • 2.9.4 Merck & Co., Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Merck & Co., Inc. Recent Developments and Future Plans
  • 2.10 Takeda Pharmaceutical Company Limited
    • 2.10.1 Takeda Pharmaceutical Company Limited Details
    • 2.10.2 Takeda Pharmaceutical Company Limited Major Business
    • 2.10.3 Takeda Pharmaceutical Company Limited Anticancer Biologics Product and Solutions
    • 2.10.4 Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
  • 2.11 Merck KGaA
    • 2.11.1 Merck KGaA Details
    • 2.11.2 Merck KGaA Major Business
    • 2.11.3 Merck KGaA Anticancer Biologics Product and Solutions
    • 2.11.4 Merck KGaA Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Merck KGaA Recent Developments and Future Plans
  • 2.12 Eli Lilly and Company
    • 2.12.1 Eli Lilly and Company Details
    • 2.12.2 Eli Lilly and Company Major Business
    • 2.12.3 Eli Lilly and Company Anticancer Biologics Product and Solutions
    • 2.12.4 Eli Lilly and Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.13 Ono Pharmaceutical Co., Ltd.
    • 2.13.1 Ono Pharmaceutical Co., Ltd. Details
    • 2.13.2 Ono Pharmaceutical Co., Ltd. Major Business
    • 2.13.3 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product and Solutions
    • 2.13.4 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Ono Pharmaceutical Co., Ltd. Recent Developments and Future Plans
  • 2.14 Pfizer Inc.
    • 2.14.1 Pfizer Inc. Details
    • 2.14.2 Pfizer Inc. Major Business
    • 2.14.3 Pfizer Inc. Anticancer Biologics Product and Solutions
    • 2.14.4 Pfizer Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Pfizer Inc. Recent Developments and Future Plans
  • 2.15 GSK plc
    • 2.15.1 GSK plc Details
    • 2.15.2 GSK plc Major Business
    • 2.15.3 GSK plc Anticancer Biologics Product and Solutions
    • 2.15.4 GSK plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 GSK plc Recent Developments and Future Plans
  • 2.16 Regeneron Pharmaceuticals, Inc.
    • 2.16.1 Regeneron Pharmaceuticals, Inc. Details
    • 2.16.2 Regeneron Pharmaceuticals, Inc. Major Business
    • 2.16.3 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product and Solutions
    • 2.16.4 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Regeneron Pharmaceuticals, Inc. Recent Developments and Future Plans
  • 2.17 Innovent Biologics, Inc.
    • 2.17.1 Innovent Biologics, Inc. Details
    • 2.17.2 Innovent Biologics, Inc. Major Business
    • 2.17.3 Innovent Biologics, Inc. Anticancer Biologics Product and Solutions
    • 2.17.4 Innovent Biologics, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Innovent Biologics, Inc. Recent Developments and Future Plans
  • 2.18 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • 2.18.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
    • 2.18.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
    • 2.18.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product and Solutions
    • 2.18.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments and Future Plans
  • 2.19 Shanghai Junshi Biosciences Co., Ltd.
    • 2.19.1 Shanghai Junshi Biosciences Co., Ltd. Details
    • 2.19.2 Shanghai Junshi Biosciences Co., Ltd. Major Business
    • 2.19.3 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product and Solutions
    • 2.19.4 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Shanghai Junshi Biosciences Co., Ltd. Recent Developments and Future Plans
  • 2.20 Akeso, Inc.
    • 2.20.1 Akeso, Inc. Details
    • 2.20.2 Akeso, Inc. Major Business
    • 2.20.3 Akeso, Inc. Anticancer Biologics Product and Solutions
    • 2.20.4 Akeso, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Akeso, Inc. Recent Developments and Future Plans
  • 2.21 Shanghai Henlius Biotech, Inc.
    • 2.21.1 Shanghai Henlius Biotech, Inc. Details
    • 2.21.2 Shanghai Henlius Biotech, Inc. Major Business
    • 2.21.3 Shanghai Henlius Biotech, Inc. Anticancer Biologics Product and Solutions
    • 2.21.4 Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.21.5 Shanghai Henlius Biotech, Inc. Recent Developments and Future Plans
  • 2.22 RemeGen Co., Ltd.
    • 2.22.1 RemeGen Co., Ltd. Details
    • 2.22.2 RemeGen Co., Ltd. Major Business
    • 2.22.3 RemeGen Co., Ltd. Anticancer Biologics Product and Solutions
    • 2.22.4 RemeGen Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.22.5 RemeGen Co., Ltd. Recent Developments and Future Plans
  • 2.23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    • 2.23.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details
    • 2.23.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
    • 2.23.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product and Solutions
    • 2.23.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.23.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
  • 2.24 Sino Biopharmaceutical Limited
    • 2.24.1 Sino Biopharmaceutical Limited Details
    • 2.24.2 Sino Biopharmaceutical Limited Major Business
    • 2.24.3 Sino Biopharmaceutical Limited Anticancer Biologics Product and Solutions
    • 2.24.4 Sino Biopharmaceutical Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.24.5 Sino Biopharmaceutical Limited Recent Developments and Future Plans
  • 2.25 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
    • 2.25.1 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Details
    • 2.25.2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Major Business
    • 2.25.3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product and Solutions
    • 2.25.4 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.25.5 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Recent Developments and Future Plans
  • 2.26 Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
    • 2.26.1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Details
    • 2.26.2 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Major Business
    • 2.26.3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product and Solutions
    • 2.26.4 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.26.5 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Anticancer Biologics Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Anticancer Biologics by Company Revenue
    • 3.2.2 Top 3 Anticancer Biologics Players Market Share in 2025
    • 3.2.3 Top 6 Anticancer Biologics Players Market Share in 2025
  • 3.3 Anticancer Biologics Market: Overall Company Footprint Analysis
    • 3.3.1 Anticancer Biologics Market: Region Footprint
    • 3.3.2 Anticancer Biologics Market: Company Product Type Footprint
    • 3.3.3 Anticancer Biologics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Anticancer Biologics Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Anticancer Biologics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Anticancer Biologics Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Anticancer Biologics Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Anticancer Biologics Consumption Value by Type (2021-2032)
  • 6.2 North America Anticancer Biologics Market Size by Application (2021-2032)
  • 6.3 North America Anticancer Biologics Market Size by Country
    • 6.3.1 North America Anticancer Biologics Consumption Value by Country (2021-2032)
    • 6.3.2 United States Anticancer Biologics Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Anticancer Biologics Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Anticancer Biologics Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Anticancer Biologics Consumption Value by Type (2021-2032)
  • 7.2 Europe Anticancer Biologics Consumption Value by Application (2021-2032)
  • 7.3 Europe Anticancer Biologics Market Size by Country
    • 7.3.1 Europe Anticancer Biologics Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Anticancer Biologics Market Size and Forecast (2021-2032)
    • 7.3.3 France Anticancer Biologics Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Anticancer Biologics Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Anticancer Biologics Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Anticancer Biologics Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Anticancer Biologics Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Anticancer Biologics Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Anticancer Biologics Market Size by Region
    • 8.3.1 Asia-Pacific Anticancer Biologics Consumption Value by Region (2021-2032)
    • 8.3.2 China Anticancer Biologics Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Anticancer Biologics Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Anticancer Biologics Market Size and Forecast (2021-2032)
    • 8.3.5 India Anticancer Biologics Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Anticancer Biologics Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Anticancer Biologics Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Anticancer Biologics Consumption Value by Type (2021-2032)
  • 9.2 South America Anticancer Biologics Consumption Value by Application (2021-2032)
  • 9.3 South America Anticancer Biologics Market Size by Country
    • 9.3.1 South America Anticancer Biologics Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Anticancer Biologics Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Anticancer Biologics Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Anticancer Biologics Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Anticancer Biologics Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Anticancer Biologics Market Size by Country
    • 10.3.1 Middle East & Africa Anticancer Biologics Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Anticancer Biologics Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Anticancer Biologics Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Anticancer Biologics Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Anticancer Biologics Market Drivers
  • 11.2 Anticancer Biologics Market Restraints
  • 11.3 Anticancer Biologics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Anticancer Biologics Industry Chain
  • 12.2 Anticancer Biologics Upstream Analysis
  • 12.3 Anticancer Biologics Midstream Analysis
  • 12.4 Anticancer Biologics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Anticancer Biologics market size was valued at US$ 114684 million in 2025 and is forecast to a readjusted size of US$ 217860 million by 2032 with a CAGR of 9.0% during review period.
    Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.
    Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.
    From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.
    The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.
    The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.
    Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.
    Report Scope
    This report is a detailed and comprehensive analysis for global Anticancer Biologics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Anticancer Biologics market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Anticancer Biologics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Anticancer Biologics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Anticancer Biologics market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Anticancer Biologics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Anticancer Biologics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Roche, Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca plc, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Anticancer Biologics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segmentation
    Market segment by Type
    Antibody Therapies
    Antibody-Drug Conjugates (ADCs)
    Cell Therapies
    Cancer Vaccines and Oncolytic Viruses
    Others
    Market segment by Target
    Immune Checkpoint Targets
    Solid Tumor-Associated Targets
    Hematologic Tumor Targets
    Angiogenesis-Related Targets
    Others
    Market segment by Route of Administration
    Intravenous Administration
    Subcutaneous Administration
    Cell Infusion
    Intratumoral Administration
    Others
    Market segment by Application
    Lung Cancer
    Breast Cancer
    Hematologic Cancers
    Gastrointestinal Cancers
    Others
    Market segment by players, this report covers
    AbbVie Inc.
    Johnson & Johnson
    Novartis AG
    Gilead Sciences, Inc.
    Roche
    Bristol-Myers Squibb Company
    Amgen Inc.
    AstraZeneca plc
    Merck & Co., Inc.
    Takeda Pharmaceutical Company Limited
    Merck KGaA
    Eli Lilly and Company
    Ono Pharmaceutical Co., Ltd.
    Pfizer Inc.
    GSK plc
    Regeneron Pharmaceuticals, Inc.
    Innovent Biologics, Inc.
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Shanghai Junshi Biosciences Co., Ltd.
    Akeso, Inc.
    Shanghai Henlius Biotech, Inc.
    RemeGen Co., Ltd.
    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Sino Biopharmaceutical Limited
    Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
    Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Anticancer Biologics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Anticancer Biologics, with revenue, gross margin, and global market share of Anticancer Biologics from 2021 to 2026.
    Chapter 3, the Anticancer Biologics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Anticancer Biologics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Anticancer Biologics.
    Chapter 13, to describe Anticancer Biologics research findings and conclusion.

    Buy now